𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients

✍ Scribed by M. Nevrly; P. Kanovsky; H. Vranova; K. Langova; P. Hlustik

Book ID
116820590
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
76 KB
Volume
15
Category
Article
ISSN
1353-8020

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Effects of levodopa and COMT inhibitors
Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients
✍ Paolo Lamberti; Stefano Zoccolella; Giovanni Iliceto; Elio Armenise; Angela Frad πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 70 KB πŸ‘ 1 views

## Abstract Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment, and dementia. Elevated plasma concentrations of Hcy have been found recently in Parkinson's disease (PD) patients treated with levodopa, suggesting that levodopa is a cause of hyperhomocysteinemia (HHcy). T

Homocysteine levels after acute levodopa
Homocysteine levels after acute levodopa intake in patients with Parkinson's disease
✍ Thomas MΓΌller; Wilfried Kuhn πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 84 KB

## Abstract Levodopa (L‐dopa) administered with a dopadecarboxylase inhibitor (DDI) increases homocysteine plasma levels. This may support the onset of atherosclerosis‐related disorders and neuropsychiatric complications in patients with Parkinson's disease (PD). This homocysteine elevation is cons